Researchers found that simultaneously blocking two key “don’t eat me signals” found in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in models of glioblastoma (GBM), highlighting a promising strategy. The study was co-led by Wen Jiang, M.D., Ph.D., associate professor of Radiation Oncology, and Betty Kim, M.D., Ph.D., professor of Neurosurgery and core member of the James P. Allison Institute™.
Low testosterone levels may be associated with an increased risk of prostate cancer progression during surveillance
A new study found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a more aggressive form while under active surveillance. The findings suggest that baseline testosterone may serve as a useful clinical marker to better stratify risk and tailor monitoring strategies for patients choosing active surveillance.